Balance Sheet
Cash Flow Statement
AmortizationAmortization of Deferred ChargesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Capital Expenditures (2023 - 2024)

Historic Capital Expenditures for BioLineRx (BLRX) over the last 2 years, with Q4 2024 value amounting to $6000.0.

  • BioLineRx's Capital Expenditures rose 13750.0% to $6000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was -$53000.0, marking a year-over-year increase of 5431.03%. This contributed to the annual value of -$53000.0 for FY2024, which is 5431.03% up from last year.
  • Per BioLineRx's latest filing, its Capital Expenditures stood at $6000.0 for Q4 2024, which was up 13750.0% from -$27000.0 recorded in Q2 2024.
  • In the past 5 years, BioLineRx's Capital Expenditures ranged from a high of $6000.0 in Q4 2024 and a low of -$67000.0 during Q2 2023